Exchange: NASDAQ·Updated 07:42 PM EDT
CVKD logo

CVKD Cadrenal Therapeutics, Inc.

$0.9095
$0.0195
(2.10%)
Today
Closed $0.9101
$0.0006
(0.07%)
After Hours
Mkt Cap$3.32M
Vol83,751.00

About CVKD

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
50

Neutral Sentiment

How do you feel about CVKD?

BobMark
$CVKD I have only spend a couple of hours reading on this. None of this makes sense. Tecarfarin shows incredible promise. Onvoloxastat shows incredible promise. Have they been hiding from BP?
1
focafoca99
$CVKD commences a strategic review to explore licensing, sales, partnerships or other transactions to maximize company value.
1
History101
$CVKD risk of dilution and reverse split, rising rates, bad season for stocks (until at least the midterms are over), then tax loss harvest season in Dec. CVKD is asymmetric to the downside right now
mebanks
$CVKD ; hope some good comes from this for the sake of the shareholders "Strategic process will consider potential asset sales, business combinations and other transactions to maximize portfolio value."

Advertisement|Remove ads.